Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
University of California, San Diego |
---|---|
Information provided by: | University of California, San Diego |
ClinicalTrials.gov Identifier: | NCT00706173 |
Developing novel and effective pharmacologic interventions for this post-traumatic stress disorder is important. We propose to replicate findings of an earlier published pilot study using low dose hydrocortisone as a treatment for PTSD. In order to do so in a more meaningful way, we will conduct a larger but similar randomized double-blind placebo-controlled, cross-over design treatment study examining the use of low dose hydrocortisone (or placebo) for 4 weeks in combat veterans suffering from PTSD.
We hypothesize that, as described by Aerni et al. (2004), administration of daily hydrocortisone will lead to a reduction in PTSD symptom severity, but particularly for re-experiencing types (e.g., flashbacks, nightmares)of symptoms. We also hope to examine potential predictors and moderators of treatment response based on subjects' clinical characteristics, as well as serum cortisol and ACTH levels.
Condition | Intervention | Phase |
---|---|---|
Post-Traumatic Stress Disorder |
Drug: Hydrocortisone Drug: Placebo |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator), Crossover Assignment, Efficacy Study |
Official Title: | A Randomized Double-Blind Placebo-Controlled Cross-Over Trial of Hydrocortisone for Post-Traumatic Stress Disorder |
Estimated Enrollment: | 40 |
Study Start Date: | June 2008 |
Estimated Study Completion Date: | June 2010 |
Estimated Primary Completion Date: | June 2010 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Active Comparator |
Drug: Hydrocortisone
Hydrocortisone 10-20 mg PO daily for 4 weeks followed by a two week washout and then switch to arm 2 for 4 weeks
|
2: Placebo Comparator |
Drug: Placebo
Placebo 10-20 mg PO daily for 4 weeks followed by a 2 week washout and then switch to arm 1 for 4 weeks
|
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Lakshmi Ravindran, MD | 858-534-7352 | lravindran@ucsd.edu |
Contact: Murray Stein, MD,MPH | mstein@ucsd.edu |
United States, California | |
University of California, San Diego | Recruiting |
La Jolla, California, United States, 92037 | |
Contact: Lakshmi Ravindran, MD 858-534-7352 lravindran@ucsd.edu | |
Principal Investigator: Murray B Stein, MD, MPH | |
Sub-Investigator: Lakshmi Ravindran, MD |
Principal Investigator: | Murray B Stein, MD,MPH | University of California, San Diego |
Responsible Party: | University of California, San Diego ( Murray B. Stein ) |
Study ID Numbers: | 071982 |
Study First Received: | June 25, 2008 |
Last Updated: | June 25, 2008 |
ClinicalTrials.gov Identifier: | NCT00706173 |
Health Authority: | United States: Institutional Review Board |
Post-traumatic stress disorder PTSD Cortisol hydrocortisone pharmacological treatment |
Hydrocortisone Cortisol succinate Anxiety Disorders Mental Disorders |
Stress Disorders, Post-Traumatic Stress Hydrocortisone acetate Stress Disorders, Traumatic |
Anti-Inflammatory Agents Pathologic Processes Disease Therapeutic Uses Pharmacologic Actions |